Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

VFC's Stock House: Synergy Pharmaceuticals (SGYP) Ready To Roll

(EMAILWIRE.COM, May 22, 2012 ) New York, NY -- VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, reported today that Synergy Pharmaceuticals (SGYP) may be in a position to realize significant share price gains over the coming months.



Synergy Pharmaceuticals (SGYP) ran to over seven dollars last month on increasing volume as the company's billion dollar potential took shape and numerous analysts jumped on board with encouraging write-ups and bold price predictions.



Synergy also received a boost when its chief competitor, Ironwood Pharmaceuticals (IRWD) received a setback at the FDA that allows SGYP an extra three months to play catch up in the race to commercialization for each company's respective product candidate, both of which target the same indication. Synergy's product Plecanatide, however, has a much more favorable side effect profile, making the Ironwood setback that much more of a key factor when discussing future market potential.



Both products, Synergy's Plecanatide and Ironwood's Linaclotide, are being developed to treat chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C). Linaclotide is already before the FDA for review, although the review was delayed by three months, as mentioned before, while Phase II/III Plecanatide results are due out later this year.



The head start to market may provide Ironwood with a distinct advantage, but the advantage might not last too long when Plecanatide shows up on the scene.



During the Linaclotide trials, the drug was successful in alleviating symptoms relating to IBS-C and CIC when compared to a placebo, but the kicker is that patients experienced side effects that included cases of extreme diarrhea, essentially reversing the symptom being treated. Some cases of diarrhea were so bad that 6% of the patients decided to abandon the trial altogether.



On the open market - with a competing product out there for which there have been no such cases noted - that means those patients would likely switch to the alternative, in this case Plecanatide, that is not associated with carrying around a roll of Charmin' Soft at all times.



For full report visit: http://vfcsstockhouse.com/blog/article/-synergy-pharmaceuticals-sgyp-may-be-ready-to-roll



For full report and opinion visit: http://vfcsstockhouse.com/blog/article/-the-facebook-fb-ipo-don-t-believe-the-hype



Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse



'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213



About VFCsStockHouse.com:



VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFCs Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.



For full disclaimer visit: http://vfcsstockhouse.com







VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News
Health News Headlines - Yahoo News
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on top health stories.


Health care site flagged in Heartbleed review
18 Apr 2014 at 10:18pm

WASHINGTON (AP) ? People who have accounts on the enrollment website for President Barack Obama's signature health care law are being told to change their passwords following an administration-wide review of the government's vulnerability to the confounding Heartbleed Internet security flaw.


Study: Half of jailed NYC youths have brain injury
18 Apr 2014 at 2:35pm
NEW YORK (AP) ? About half of all 16- to 18-year-olds coming into New York City's jails say they had a traumatic brain injury before being incarcerated, most caused by assaults, according to a new study that's the latest in a growing body of research documenting head trauma among young offenders.

Second wave of milder flu hitting Northeast
18 Apr 2014 at 2:25pm
NEW YORK (AP) ? A second, milder wave of flu is hitting the Northeast.


Pfizer mulls $100 billion bid for AstraZeneca: report
20 Apr 2014 at 3:48am

U.S. pharmaceutical giant Pfizer has approached British rival AstraZeneca to propose a 60 billion pound ($101 billion) takeover, the Sunday Times reported on Sunday. The paper said, citing senior investment bankers and industry sources, that informal conversations about a deal had taken place between the two firms but that no talks were currently under way after AstraZeneca resisted the approach. AstraZeneca is Britain's second-biggest pharmaceuticals group with a current market valuation of around $80 billion, compared with Pfizer, which is valued at $193 billion, according to Thomson Reuters data. Earnings at AstraZeneca fell 6 percent in the fourth quarter of 2013, and the drugmaker has said it expects them to keep falling in 2014 as generic competition to Nexium, its popular heartburn and ulcer drug, takes a big bite out of U.S. profits from late May. AstraZeneca has suffered a dry period in drug discovery in recent years and badly needs to find new medicines to replace blockbusters such as Nexium and Crestor, a treatment for high cholesterol that will lose patent protection in a few years.


Saudi Arabia announces jump in new cases of deadly MERS virus
20 Apr 2014 at 3:37am
Saudi Arabia has confirmed seven new cases of Middle East Respiratory Syndrome (MERS), adding up to 36 infections in five days, a sudden increase of a disease that kills about a third of the people infected and has no cure. MERS, a SARS-like novel coronavirus that emerged in Saudi Arabia two years ago, has infected 231 people in the kingdom, of whom 76 have died, the Health Ministry said on its website. Meanwhile, another cluster of cases has been detected in the United Arab Emirates, and a Malaysian who was recently in the Gulf has been confirmed as infected, his country said. MERS has no vaccine or anti-viral treatment, but international and Saudi health authorities say the disease, which originated in camels, does not transmit easily between people and may simply die out.


On Easter, Pope calls for end to war, condemns waste exacerbating hunger
20 Apr 2014 at 3:35am

By Philip Pullella VATICAN CITY (Reuters) - Pope Francis, in his Easter address before a huge crowd, on Sunday denounced the "immense wastefulness" in the world while many go hungry and called for an end to conflicts in Syria, Ukraine and Africa. "We ask you, Lord Jesus, to put an end to all war and every conflict, whether great or small, ancient or recent," he said in his "Urbi et Orbi" (to the city and the world) message. Francis, marking the second Easter season of his pontificate, celebrated a Mass to an overflowing crowd of at least 150,000 in St. Peter's Square and beyond.



Obamacare enrollees urged to change passwords over Heartbleed bug
19 Apr 2014 at 8:56pm

By Chris Francescani NEW YORK (Reuters) - Americans with accounts on President Barack Obama's health insurance enrollment website, HealthCare.gov, were advised that their passwords had been reset to guard against the "Heartbleed" bug, in a message posted on the site on Saturday. The warning marks the latest fallout from the widespread security bug, which surfaced this month and allows hackers to steal data online without a trace. Companies from Amazon.com Inc to Google Inc. have been forced to take steps to protect against Heartbleed. HealthCare.gov, a health insurance exchange for the 36 states that opted out of creating their own state insurance exchanges, was created under Obama's signature health care law, the 2010 Patient Protection and Affordable Care Act.



Woman With Engineered Vagina Says She Has 'Normal Life'
19 Apr 2014 at 1:00pm

Researchers Were Able to Engineer Organs From Patient's Own Cells


Gunmen kidnap two Pakistani U.N. staff members from Karachi
19 Apr 2014 at 1:08am
By Syed Raza Hassan ISLAMABAD (Reuters) - Gunmen have kidnapped two men working for the U.N. Children's Fund from Pakistan's southern city of Karachi, police said Saturday. A spokeswoman for the U.N. Children's Fund, also known as UNICEF, was not available to comment. The port city of Karachi is Pakistan's financial heart and home to 18 million people. Many neighborhoods are considered Taliban strongholds, including the area of Shorab Goth, which is near where the men were taken.

APNewsBreak: Medicaid paid $12M for Illinois dead
18 Apr 2014 at 4:42pm
CHICAGO (AP) ? The Illinois Medicaid program paid an estimated $12 million for medical services for people listed as deceased in other state records, according to an internal state government memo.

Watch: Scientists Engineer Lab-Grown Vaginas
18 Apr 2014 at 3:03pm
Four women with a genetic condition took part in a ground-breaking study.

Yoga may help women ease PTSD symptoms
18 Apr 2014 at 2:36pm
By Shereen Jegtvig NEW YORK (Reuters Health) - Women enrolled in a small study reported a reduction in symptoms of posttraumatic stress disorder (PTSD) after a series of yoga classes. However, women in a comparison group that didn't take the classes also reported a similar decline in symptoms, researchers found. "The yoga group did well - they improved in their PTSD symptoms - and our control group actually did well, which we didn't expect," Karen Mitchell told Reuters Health. Mitchell, from the National Center for PTSD at the VA Boston Healthcare System, led the new study.


Supreme Court denies Teva stay in Copaxone patent fight
18 Apr 2014 at 1:49pm

By Lawrence Hurley WASHINGTON (Reuters) - U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd to stay a lower-court ruling in a patent case that favored the developers of generic versions of Teva's top-selling multiple sclerosis drug. The decision could help pave the way for generic competitors of Teva's Copaxone drug to go on the market as soon as next month. Teva had sought to prevent the lower-court ruling from going into effect while the Supreme Court considers its appeal in the patent fight. At issue is a July 2013 ruling by the U.S. Court of Appeals for the Federal Circuit in favor of two teams developing cheaper generic forms of Copaxone: one comprising Novartis AG's Sandoz Inc and Momenta Pharmaceuticals Inc, and the other comprising Mylan Inc and Natco Pharma Ltd. In his decision on Friday, Roberts, in a brief opinion, wrote that he was not convinced Teva had shown the "likelihood of irreparable harm" if the application was denied, because if Teva wins the Supreme Court case it can seek damages from the generic companies for past infringement on its patents.


AbbVie urges U.S. court to avoid gay rights issue in HIV drug case
18 Apr 2014 at 12:57pm
An Abbott Laboratories spinoff urged a federal appeals court to revisit a ruling in a case against GlaxoSmithKline Plc, but without disturbing landmark constitutional protections for gays and lesbians. In a brief filed with the 9th U.S. Circuit Court of Appeals in San Francisco on Thursday, AbbVie Inc said the full court should review an initial three-judge decision that found a gay man was improperly excluded from jury service due to his sexual orientation. The court in reaching that conclusion in January ordered a new trial for GlaxoSmithKline Plc against AbbVie, which contended Thursday that the 9th Circuit's ruling needed review due to its potential to affect "thousands of jury trials." But AbbVie said it is not asking for the court to reconsider a holding that heightened the constitutional protections judges in several Western states must now apply when evaluating laws that curtail gay rights.


Top Hollande aide quits in conflict of interest row
18 Apr 2014 at 12:43pm

By Julien Ponthus and Nicholas Vinocur CLERMONT-FERRAND, France (Reuters) - A senior adviser to French President Francois Hollande quit on Friday over accusations of past conflict of interest linked to his work for pharmaceutical firms, adding to pressure on the unpopular Socialist leader weeks before European elections. Aquilino Morelle, Hollande's chief communications adviser, speechwriter and a main political strategist, has denied investigative website Mediapart's report that he had failed to obtain clearance for lobbying work when he was an employee of the public health inspectorate. The furore deals another blow to Hollande after heavy losses for his party in town hall elections at the end of March. Hollande, speaking during a visit to Clermont Ferrand in central France, said his aide had "taken the only option open to him".


Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC